Stockscreener 앱 받기
81.48
18.07%
12.47
시간 외 거래:
80.58
-0.90
-1.10%
전일 마감가:
$69.01
열려 있는:
$77.86
하루 거래량:
2.10M
Relative Volume:
5.64
시가총액:
$1.76B
수익:
$486.82M
순이익/손실:
$18.78M
주가수익비율:
99.37
EPS:
0.82
순현금흐름:
$100.45M
1주 성능:
+27.45%
1개월 성능:
+25.22%
6개월 성능:
+34.57%
1년 성능:
+44.39%
1일 변동 폭
$76.98
$83.80
1주일 범위
$63.67
$83.80
52주 변동 폭
$52.50
$83.80
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
명칭
Ani Pharmaceuticals Inc
전화
(218) 634-3500
주소
210 MAIN STREET WEST, BAUDETTE, MN
ANIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
81.48 | 1.50B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
147.35 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.54 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.37 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.50 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 개시 | H.C. Wainwright | Buy |
| 2025-03-14 | 개시 | Jefferies | Buy |
| 2025-03-12 | 개시 | JP Morgan | Overweight |
| 2024-12-11 | 개시 | Leerink Partners | Outperform |
| 2024-10-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-15 | 개시 | CapitalOne | Overweight |
| 2023-08-22 | 재확인 | H.C. Wainwright | Buy |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2022-09-07 | 개시 | H.C. Wainwright | Buy |
| 2021-11-02 | 개시 | Truist | Buy |
| 2020-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-05-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 재확인 | Canaccord Genuity | Buy |
| 2017-07-31 | 개시 | Canaccord Genuity | Buy |
| 2017-02-22 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 개시 | Raymond James | Strong Buy |
| 2016-05-24 | 다운그레이드 | Standpoint Research | Buy → Hold |
| 2015-11-13 | 개시 | Standpoint Research | Buy |
| 2015-09-28 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 재확인 | Oppenheimer | Outperform |
| 2015-08-04 | 재확인 | ROTH Capital | Neutral |
| 2015-07-31 | 재확인 | Oppenheimer | Outperform |
| 2015-07-15 | 재확인 | ROTH Capital | Neutral |
| 2015-06-23 | 재확인 | Oppenheimer | Outperform |
| 2015-05-18 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 재확인 | Oppenheimer | Outperform |
| 2015-04-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 재확인 | ROTH Capital | Buy |
| 2015-02-18 | 재확인 | Oppenheimer | Outperform |
모두보기
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
ANI Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
ANI Pharmaceuticals: A High-Growth Biopharma Play with Rare Disease and Generics Synergy - AInvest
Assessing ANI Pharmaceuticals' (ANIP) Growth Trajectory in Rare Diseases and Generics Amid Strategic and Financial Headwinds - AInvest
ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates - MSN
Advanced analytics toolkit walkthrough for ANI Pharmaceuticals Inc.Free Buy Signal Based on Chart Analysis - Newser
ANI Pharmaceuticals Receives Buy Rating and Optimistic Price Target - timothysykes.com
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Trend analysis for ANI Pharmaceuticals Inc. this weekFree Portfolio Diversification Stock Ideas - Newser
Will ANI Pharmaceuticals Inc. rebound enough to break evenFree Short Term Buy List With Stop Protection - Newser
Should I buy ANI Pharmaceuticals Inc. stock before earningsFree Weekly Watchlist of High Movers - Newser
ANI Pharma Stock Shoots Through The Roof On Friday: CEO’s Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - MSN
ANI Pharmaceuticals Inc. stock daily chart insightsFree Fundamental + Technical Hybrid Stock Tips - Newser
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week High Following Earnings Beat - Defense World
ANI Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Highlights: Record Revenue and Raised ... By GuruFocus - Investing.com Canada
Published on: 2025-08-09 00:38:02 - Newser
ANI Pharmaceuticals Reports Record Growth in Q2 2025 - TipRanks
ANI Pharmaceuticals' Q2 2025: Unpacking Contradictions in Cortrophin Growth and Market Dynamics - AInvest
ANI Pharmaceuticals stock price target raised to $93 from $84 at H.C. Wainwright - Investing.com Canada
ANI: Q2 Earnings Snapshot - Norwalk Hour
Quantitative breakdown of ANI Pharmaceuticals Inc. recent moveFree Low Risk Buy Zone Opportunity Watch - Newser
ANI Pharmaceuticals price target raised to $93 from $84 at H.C. Wainwright - TipRanks
Why ANI Pharmaceuticals (ANIP) Stock Is Up Today - TradingView
ANI Pharmaceuticals Stock Surges After Buy Rating and Strong Price Target - StocksToTrade
ANI Pharmaceuticals Surges as Buy Rating Hits Market - timothysykes.com
Earnings call transcript: ANI Pharmaceuticals Q2 2025 earnings beat forecasts - Investing.com
Transcript : ANI Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
ANI Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ani Pharmaceuticals stock hits 52-week high at 77.86 USD By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals reports Q2 adjusted EPS $1.80, consensus $1.42 - TipRanks
Cg Oncology (CGON) Q2 Loss Widens 93% - The Motley Fool
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
How high can ANI Pharmaceuticals Inc. stock goInvestment Position Summary with Timeframe Forecast - Newser
ANI Pharmaceuticals Boosts FY25 Outlook; Stock Up 7%Update - Nasdaq
ANI Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2025 Guidance Raised - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results - TradingView
ANI PHARMACEUTICALS INC SEC 10-Q Report - TradingView
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2: Strong Sales, Stock Soars - TradingView
ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast - MarketScreener
(ANIP) ANI Pharmaceuticals Expects 2025 Revenue Range $818M$843M, vs. FactSet Est of $791.5M - MarketScreener
Record Q4 net revenues up 53.1% YoY to $211.4mln, raises FY23 guidance. - AInvest
(ANIP) ANI Pharmaceuticals Expects Full-Year 2025 Adjusted EPS Range $6.98$7.35, vs. FactSet Est of $6.53 - MarketScreener
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $211.4M, vs. FactSet Est of $190.1M - MarketScreener
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance - GlobeNewswire
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $1.80 per Share, vs. FactSet Est of $1.41 - MarketScreener
ANI Pharma Stock Shoots Through The Roof On Friday: CEO's Confidence On Trump Tariff Impact, Guidance Lift, Upbeat Q2 Among Key Factors - Menafn
How ANI Pharmaceuticals Inc. stock performs during market volatilityRSI Divergence and Support Breakout Analysis - Newser
Earnings Preview For ANI Pharmaceuticals - 富途牛牛
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Envestnet Asset Management Inc. - Defense World
ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday - Defense World
ANI Pharmaceuticals (ANIP) Q2 Earnings: What To Expect - MSN
Ani Pharmaceuticals Inc (ANIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.43%
0.47%
자본화:
|
볼륨(24시간):